Taken together, the data suggest that there is differential modulation of LRH-1 activity between ER-positive and ER-negative tumours, and that LRH-1 has roles in ER-associated, but ER-independent pathways in ER-negative tumours, similar to the observations made in breast cancer cell lines [11]. This evidence concerns the gene ESR1 and breast carcinoma.